Tempus AI (NASDAQ:TEM) Stock Price Down 7.9% – Should You Sell?

Tempus AI, Inc. (NASDAQ:TEM)’s stock price traded down 7.9% during trading on Monday . The stock traded as low as $31.36 and last traded at $34.55. 3,300,319 shares changed hands during trading, a decline of 4% from the average session volume of 3,431,535 shares. The stock had previously closed at $37.52.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. Wolfe Research began coverage on shares of Tempus AI in a report on Friday, December 13th. They set an “outperform” rating and a $60.00 price objective on the stock. Loop Capital dropped their price target on Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a research note on Tuesday. Bank of America raised their price objective on Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a research note on Friday, December 13th. Piper Sandler reiterated a “neutral” rating and issued a $70.00 target price (up previously from $40.00) on shares of Tempus AI in a research report on Tuesday, November 12th. Finally, Guggenheim assumed coverage on shares of Tempus AI in a report on Monday, December 9th. They issued a “buy” rating and a $74.00 price target on the stock. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $56.36.

Tempus AI Stock Up 9.7 %

The business has a fifty day moving average of $47.68 and a two-hundred day moving average of $47.26. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17.

Insider Transactions at Tempus AI

In other Tempus AI news, Director David R. Epstein sold 620 shares of the business’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $41.81, for a total transaction of $25,922.20. Following the completion of the sale, the director now directly owns 27,894 shares in the company, valued at approximately $1,166,248.14. The trade was a 2.17 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Eric P. Lefkofsky sold 187,655 shares of the firm’s stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $37.54, for a total value of $7,044,568.70. Following the completion of the transaction, the chief executive officer now owns 9,557,283 shares in the company, valued at approximately $358,780,403.82. This trade represents a 1.93 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 865,041 shares of company stock valued at $35,917,673 in the last three months.

Institutional Trading of Tempus AI

Several large investors have recently made changes to their positions in TEM. Kovitz Investment Group Partners LLC purchased a new position in Tempus AI in the 3rd quarter valued at $1,367,000. Sumitomo Mitsui Trust Group Inc. raised its position in shares of Tempus AI by 1,591.2% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,217,699 shares of the company’s stock valued at $68,922,000 after buying an additional 1,145,698 shares during the last quarter. Captrust Financial Advisors acquired a new stake in shares of Tempus AI in the third quarter valued at about $2,726,000. Dakota Wealth Management purchased a new position in shares of Tempus AI in the third quarter worth about $1,185,000. Finally, Sigma Planning Corp acquired a new position in Tempus AI during the third quarter worth about $1,323,000. 24.22% of the stock is currently owned by hedge funds and other institutional investors.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.